You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 15, 2024

Details for Patent: 10,835,492

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,835,492 protect, and when does it expire?

Patent 10,835,492 protects VYXEOS and is included in one NDA.

This patent has forty-three patent family members in twenty-one countries.

Summary for Patent: 10,835,492

Title:	Method of lyophilizing liposomes
Abstract:	Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Inventor(s):	Cabral-Lilly; Donna (Pennington, NJ), Mayer; Lawrence (North Vancouver, CA), Tardi; Paul (Surrey, CA), Watkins; David (East Greenwich, RI), Zeng; Yi (Somerset, NJ)
Assignee:	CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)
Application Number:	16/181,203
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,835,492

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Celator Pharms	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,835,492

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2768484	⤷ Sign Up	301016	Netherlands	⤷ Sign Up
European Patent Office	2768484	⤷ Sign Up	LUC00135	Luxembourg	⤷ Sign Up
European Patent Office	2768484	⤷ Sign Up	CA 2019 00051	Denmark	⤷ Sign Up
European Patent Office	2768484	⤷ Sign Up	122019000091	Germany	⤷ Sign Up
European Patent Office	2768484	⤷ Sign Up	CR 2019 00051	Denmark	⤷ Sign Up
European Patent Office	2768484	⤷ Sign Up	2019C/545	Belgium	⤷ Sign Up
European Patent Office	2768484	⤷ Sign Up	132019000000144	Italy	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.